Early studies assessing mTOR inhibitor efficacy in heavily pretreated cervical cancer patients observed low objective response rates yet notably high rates of temporary disease control in up to 60% of patients with incurable disease, while mTOR inhibition appears relatively safe and well tolerated. The gene discussed is MTOR; the disease is cervical carcinoma.